SAN FRANCISCOSurvival rates are significantly higher for women who
have outer quadrant breast cancer, when compared with patients who have an
inner quadrant lesion, according to results presented at the 43rd Annual
Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO
abstract 198). At 20 years, the improvement in survival for women with outer
quadrant lesions ranged from 2.2% to 9.4%, depending on age group.
These findings confirm the results of three recent studies that have also
shown a favorable hazard ratio for outer quadrant disease, said David K.
Gaffney, MD, PhD, assistant professor of radiation oncology, Huntsman Cancer
Institute, University of Utah, Salt Lake City.
This retrospective study used data from the Surveillance, Epidemiology and
End-Results (SEER) registries on 153,368 women with invasive disease diagnosed
from 1973 to 1997. Slightly less than two thirds (96,563) had local disease
(node negative), while more than one third (56,805) had regional involvement.
Patients were divided into four groups based on age: under 45, 46 to 55, 56
to 65, and 66 and over. The median duration of follow-up was 39 months. Women
with inner quadrant involvement were more likely to have local disease (70.8%
vs 61.4% for the women with outer quadrant lesions).
Patients with localized disease in all four age groups who had inner and
central lesions were less likely to survive (P = .0001 to .0002). For patients with regional disease, only women in the
younger-than-45 age group had an increased survival with outer quadrant disease
(P = .002). After 20 years, there was a 5.2% increase in survival in this
On multivariate analysis for breast-cancer-specific survival, Dr. Gaffney
said, the hazard ratio for inner quadrant location, compared with outer
quadrant, was 1.40 (95% confidence interval, 1.23-1.60) for local stage, and
1.36 (95% confidence interval, 1.22-1.51) for regional stage (see Figure for
data on a specific subset).
"Patients with local and regional stage disease had a significant
difference in breast-cancer-specific survival," Dr. Gaffney concluded.